×
About 9,695 results

ALLMedicine™ Cutaneous Melanoma Center

Research & Reviews  4,693 results

High discordance rate in assessing sentinel node positivity in cutaneous melanoma: Expe...
https://doi.org/10.1016/j.ejca.2021.03.001
European Journal of Cancer (Oxford, England : 1990); El Sharouni MA, Laeijendecker AE et. al.

Apr 13th, 2021 - Identification of sentinel node (SN) metastases can set the adjuvant systemic therapy indication for patients with stage III melanoma. Studies re-evaluating the diagnosis of initially positive SN biopsies are scarce. Dutch patients with melanoma w...

Treatment of Cutaneous Melanoma of the Head and Neck With Wide Local Excision Versus Mohs.
https://doi.org/10.1002/lary.29570
The Laryngoscope; Namin AW, Oudin EM et. al.

Apr 12th, 2021 - Determine if Mohs micrographic surgery (MMS) is associated with improved overall survival compared to wide local excision (WLE) when treating cutaneous melanoma of the head and neck (CMHN) and to report the proportion of patients treated with MMS ...

Genomic Risk Score for Melanoma in a Prospective Study of Older Individuals.
https://doi.org/10.1093/jnci/djab076
Journal of the National Cancer Institute; Bakshi A, Yan M et. al.

Apr 10th, 2021 - Recent genome-wide association meta-analysis for melanoma doubled the number of previously identified variants. We assessed the performance of an updated polygenic risk score (PRS) in a population of older individuals, where melanoma incidence and...

Gene expression and immune infiltration in melanoma patients with different mutation bu...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8034108
BMC Cancer; Wang L, Chen F et. al.

Apr 10th, 2021 - Immunotherapy is a vital component in cancer treatment. However, due to the complex genetic bases of cancer, a clear prediction index for efficacy has not been established. Tumor mutation burden (TMB) is one of the essential factors that affect im...

Genomic Landscape of Malignant Peripheral Nerve Sheath Tumor-like Melanoma.
https://doi.org/10.1016/j.jid.2021.03.016
The Journal of Investigative Dermatology; Muniz TP, Sorotsky H et. al.

Apr 8th, 2021 - Malignant peripheral nerve sheath tumor (MPNST)-like melanoma is a rare malignancy with overlapping characteristics of both neural sarcoma and melanoma. Although the genomics of cutaneous melanoma have been extensively studied, those of MPNST-like...

see more →

Guidelines  29 results

Systemic Therapy for Melanoma: ASCO Guideline.
https://doi.org/10.1200/JCO.20.00198
Journal of Clinical Oncology : Official Journal of the Am... Seth R, Messersmith H et. al.

Apr 1st, 2020 - To provide guidance to clinicians regarding the use of systemic therapy for melanoma. ASCO convened an Expert Panel and conducted a systematic review of the literature. A systematic review, one meta-analysis, and 34 additional randomized trials we...

Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
https://jnccn.org/view/journals/jnccn/17/4/article-p367.xml

Mar 31st, 2019 - For adjuvant treatment of melanoma in patients rendered free of disease by surgery, traditional systemic therapy approaches have proven to be ineffective. Adjuvant interferon alfa (IFN alfa), particularly high-dose IFN alfa, has been widely used i...

Guidelines of care for the management of primary cutaneous melanoma.
https://doi.org/10.1016/j.jaad.2018.08.055
Journal of the American Academy of Dermatology; Swetter SM, Tsao H et. al.

Nov 5th, 2018 - The incidence of primary cutaneous melanoma continues to increase each year. Melanoma accounts for the majority of skin cancer-related deaths, but treatment is usually curative following early detection of disease. In this American Academy of Derm...

An update on the Society for Immunotherapy of Cancer consensus statement on tumor immun...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5977556
Journal for Immunotherapy of Cancer; Sullivan RJ, Atkins MB et. al.

May 31st, 2018 - Cancer immunotherapy has been firmly established as a standard of care for patients with advanced and metastatic melanoma. Therapeutic outcomes in clinical trials have resulted in the approval of 11 new drugs and/or combination regimens for patien...

An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunother...
https://jitc.biomedcentral.com/articles/10.1186/s40425-018-0362-6
Sullivan, R.

May 29th, 2018 - Cancer immunotherapy has been firmly established as a standard of care for patients with advanced and metastatic melanoma. Therapeutic outcomes in clinical trials have resulted in the approval of 11 new drugs and/or combination regimens for patien.

see more →

Drugs  1 results see all →

Clinicaltrials.gov  4,831 results

High discordance rate in assessing sentinel node positivity in cutaneous melanoma: Expe...
https://doi.org/10.1016/j.ejca.2021.03.001
European Journal of Cancer (Oxford, England : 1990); El Sharouni MA, Laeijendecker AE et. al.

Apr 13th, 2021 - Identification of sentinel node (SN) metastases can set the adjuvant systemic therapy indication for patients with stage III melanoma. Studies re-evaluating the diagnosis of initially positive SN biopsies are scarce. Dutch patients with melanoma w...

Treatment of Cutaneous Melanoma of the Head and Neck With Wide Local Excision Versus Mohs.
https://doi.org/10.1002/lary.29570
The Laryngoscope; Namin AW, Oudin EM et. al.

Apr 12th, 2021 - Determine if Mohs micrographic surgery (MMS) is associated with improved overall survival compared to wide local excision (WLE) when treating cutaneous melanoma of the head and neck (CMHN) and to report the proportion of patients treated with MMS ...

Genomic Risk Score for Melanoma in a Prospective Study of Older Individuals.
https://doi.org/10.1093/jnci/djab076
Journal of the National Cancer Institute; Bakshi A, Yan M et. al.

Apr 10th, 2021 - Recent genome-wide association meta-analysis for melanoma doubled the number of previously identified variants. We assessed the performance of an updated polygenic risk score (PRS) in a population of older individuals, where melanoma incidence and...

Gene expression and immune infiltration in melanoma patients with different mutation bu...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8034108
BMC Cancer; Wang L, Chen F et. al.

Apr 10th, 2021 - Immunotherapy is a vital component in cancer treatment. However, due to the complex genetic bases of cancer, a clear prediction index for efficacy has not been established. Tumor mutation burden (TMB) is one of the essential factors that affect im...

Genomic Landscape of Malignant Peripheral Nerve Sheath Tumor-like Melanoma.
https://doi.org/10.1016/j.jid.2021.03.016
The Journal of Investigative Dermatology; Muniz TP, Sorotsky H et. al.

Apr 8th, 2021 - Malignant peripheral nerve sheath tumor (MPNST)-like melanoma is a rare malignancy with overlapping characteristics of both neural sarcoma and melanoma. Although the genomics of cutaneous melanoma have been extensively studied, those of MPNST-like...

see more →

News  141 results

Mohs Surgery May Not Boost Survival Over Standard Excision of Melanomas on Trunk, Extremities
https://www.medscape.com/viewarticle/940003

Oct 29th, 2020 - NEW YORK (Reuters Health) - Compared with wide local excision (WLE), Mohs micrographic surgery (MMS) does not appear to increase overall survival in patients with trunk or extremity melanomas, according to a retrospective study. "In contrast to ou...

Melanoma Patients Still at Higher Risk for New Malignancy After Successful Systemic Immunotherapy
https://www.medscape.com/viewarticle/938007

Sep 24th, 2020 - NEW YORK (Reuters Health) - Patients successfully treated for metastatic melanoma with immune-checkpoint inhibitors remain at increased risk for developing new primary cutaneous melanoma, according to a new study. "The 5-year risk was nearly 5%," ...

Melanoma Patients Still at Higher Risk for New Malignancy After Successful Systemic Immunotherapy
https://www.staging.medscape.com/viewarticle/938007

Sep 24th, 2020 - NEW YORK (Reuters Health) - Patients successfully treated for metastatic melanoma with immune-checkpoint inhibitors remain at increased risk for developing new primary cutaneous melanoma, according to a new study. "The 5-year risk was nearly 5%," ...

Melanoma Experts Say 'No' to Routine Gene Profile Testing
https://www.medscape.com/viewarticle/936364

Aug 25th, 2020 - An international panel of 49 melanoma specialists has come out against routine gene expression profile (GEP) testing for cutaneous melanoma, pending solid proof of clinical benefit. "The currently published evidence is insufficient to establish th...

Fast Five Quiz: Malignant Melanoma
https://reference.medscape.com/viewarticle/936083_4

Aug 20th, 2020 - Four major clinicopathologic subtypes of primary cutaneous melanoma have been identified, although newer classifications of melanoma include location on chronically sun-exposed vs intermittently or non–sun-exposed skin and incorporate the presence...

see more →